These results suggest that VPA may function as an SVCT2 inducer, providing a promising avenue for future investigations into its potential role in enhancing high-dose AA therapy in patients with cancer exhibiting low SVCT2 expression. This evidence concerns the gene SLC23A2 and cancer.